China NMPA Inspection - Changchun Botai Pharmaceutical Biotechnology Co., Ltd. - June 29, 2021

The Jilin Provincial Drug Administration officially announced the cancellation of the Cosmetics Production License for Changchun Botai Pharmaceutical Biotechnology Co., Ltd. The announcement, published on June 29, 2021, details an administrative action taken in accordance with Article 25 of the "Cosmetics Production Licensing Work Specifications." This regulatory framework governs the licensing and oversight of cosmetic manufacturing entities within China. The company, located at No. 1050, Guanggu Street, Changchun High-tech Zone, and with Liu Tao as its legal representative, previously held license number Jizhuang 20190004. This license authorized the production of "General Liquid Unit (Skin Care Water)." It is important to note that the license cancellation was not a result of any inspection findings, non-compliance, or violations; rather, it was explicitly due to the enterprise's voluntary application. This indicates a self-initiated decision by Changchun Botai Pharmaceutical Biotechnology Co., Ltd. to cease its licensed manufacturing operations. The required action was the formal and public revocation of the company's authorization to produce cosmetics, ensuring transparency within the regulated industry under the broader National Medical Products Administration system.